NEW FACTS ABOUT...

Stroke in older adults

troke is a leading cause of serious long-term disability¹ and the third leading cause of death in the United States.² About 72 percent of people who suffer from a stroke in any given year are over age 65, and more than 88 percent of the deaths resulting from stroke occur in this population.¹ It affects between 6 percent and 8 percent of community-dwelling elders over age 65.³ Moreover, for people over age 55, the incidence of stroke more than doubles with each successive decade.¹ Established risk factors for stroke include prior stroke, hypertension, cigarette smoking, atrial fibrillation (AF), transient ischemic attacks (TIAs) and elevated cholesterol.⁴⁵ Among those aged 65–74, 57 percent of men and 61 percent of women have high blood pressure.¹ Both active and passive cigarette smoking play a major role in the progression of atherosclerosis.⁶⁷ The attributable risk of stroke from AF increases strikingly with age from 3 percent among those aged 60–69 years to 24 percent of those aged 80–89 years.⁶ A history of TIAs suggests someone is nearly 10 times more at risk for a stroke than someone of the same sex and age without this same history.⁴ Cardiac risk factors shown to increase the risk of stroke include valvular heart disease, myocardial infarction, coronary artery disease, heart failure and electrocardiographic evidence of left ventricular hypertrophy.⁶ In diabetics, the relative risk of ischemic stroke ranges from 1.5 to 3.0 and probably depends on the severity and type of diabetes.⁶

Given the poor outcomes associated with stroke, methods to prevent stroke have received research priority. The following are some findings in the recent literature related to the prevention and management of stroke:

There is a 34–35 percent reduction in stroke among hypertensive elders treated with blood pressure lowering medications. 10,11

In patients under 75 years with AF who do not have a history of hypertension, cardioembolus, or heart failure, direct evidence indicates that, compared to a placebo, aspirin reduces the risk of stroke, and, compared to aspirin, warfarin further reduces the risk.¹²⁻¹⁶

Direct evidence supports the use of carotid endarterectomy for male patients with symptomatic disease (manifested by transient ischemic attacks [TIAs], small stroke, or stroke with recovery in the side ipsilateral to stenosis) who receive surgery at hospitals with low (<6 percent) 30-day morbidity and mortality rates. ^{17,18} A similar conclusion for women could not be reached since an insufficient number were enrolled in the clinical trials.

Direct evidence also supports the use of carotid endarterectomy for male patients with high-grade stenosis who are asymptomatic and have lower surgical risk (<3 percent). A similar conclusion for women could not be reached since an insufficient number were enrolled in the clinical trials.

Admission to specialized stroke units has been shown to improve multiple outcomes, including physical function, quality of life, survival rate, and length of hospitalization.^{21–26}

There are effective ways to help prevent stroke and to improve outcomes for patients who have stroke. However, very few clinical studies have focused directly on the vulnerable elderly, a significant deficiency given that these individuals have such a high incidence of stroke.

This information is an interim result of a funded three-year collaboration between Pfizer and RAND to measure and improve the quality of care provided for older Americans.





References

- 1. American Heart Association. *Older Americans and Cardiovascular Diseases: Biostatistical Fact Sheets.* http://www.americanheart.org/statistics/biostats/biool.htm.
- 2. Hoyert DL, Kochanek KD, Murphy SL. *Deaths: Final Data for 1997.* National Vital Statistics Reports; Vol 47, No. 19. Hyattsville, Maryland: National Center for Health Statistics. 1999.
- 3. Collins, JG. Prevalence of Selected Chronic Conditions: United States, 1990–1992. National Center for Health Statistics. Vital Health Statistics. 1997;10(194).
- 4. American Heart Association. *Stroke Risk Factors*. http://www.amhrt.org/Heart_and Stroke_A_Z_Guide/strokeri.html.
- 5. Quizilbash N, Duffy SW, Warlow C, Mann I. Lipids are risk factors for ischemic stroke: overview and review. *Cerebrovascular Disease*. 1992:2: 127–136.
- 6. Howard G, Wagenknecht LE, Burke GL, Diez-Roux A, Evans GW, McGovern P, Nieto J, Tell GS. Cigarette smoking and progression of atherosclerosis: The Atherosclerosis Risk in Communities (ARIC) study. *JAMA*. 1998;279:119–124.
- 7. Howard G, Wagenknecht LE, Cai J, Cooper L, Draut MA, Toole JF. Cigarette Smoking and other risk factors for silent cerebral infarction in the general population. *Stroke*. 1998;29:913–917.
- 8. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: The Framingham study. *Stroke*. 1991;22:983–988.
- 9. Sacco RL, "Ischemic Stroke." In: Gorelick PB. *Handbook of Neuroepidemiology*. New York, NY. Marcel Dekker, Inc. 1994:77–119.
- 10. Insua JT, Sacks HS, Lau T-S, Lau J, Reitman D, Pagano D, Chalmers TC. Drug treatment of hypertension in the elderly: A meta-analysis. *Ann Intern Med.* 1994;121:355–362.
- 11. MacMahon S, Rodgers, A. The effects of blood pressure reduction in older patients: An overview of five randomized controlled trials in elderly hypertensives. *Clin and Exper Hypertension*. 1993;15:967–978.
- 12. Atrial Fibrillation Investigators. Risk factors for stroke and efficacy of antithrombotic therapy in atrial fibrillation: Analysis of pooled data from five randomized controlled trials. *Arch Intern Med.* 1994;154:1449–1457.
- 13. Prystowsky EN, Benson W, Fuster V, Hart RG, Kay GN, Myerburg RJ, Naccarelli GV, Wyse DG. Management of patients with atrial fibrillation: A statement for healthcare professionals from the Subcommittee on Electrocardiography and Electrophysiology, American Heart Association. *Circulation*. 1996:93:1262–1277.

- 14. Caplan LR. Stroke treatment: Promising but still struggling. *JAMA*. 1998:279:1304–1306.
- 15. Petersen P, Boysen G, Godtfredsen J, Andersen ED, Andersen B. Placebocontrolled, randomised trial of warfarin and aspirin for prevention of thromboembolic complications in chronic atrial fibrillation: The Copenhagen AFASAK study. *Lancet.* 1989;1:175–179.
- 16. Stroke Prevention in Atrial Fibrillation Investigators. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II study. *Lancet*. 1994;343:687–691.
- 17. North American Symptomatic Carotid Endarterectomy Trial Collaborators. Beneficial effect of carotid endarterectomy in symptomatic patients with high-grade stenosis. *N Engl J Med.* 1991;325:445–453.
- 18. European Carotid Surgery Trialists' Collaborative Group. MRC European Carotid Surgery Trial: Interim results for symptomatic patients with severe (70–99%) or with mild (0–29%) carotid stenosis. *Lancet.* 1991; 337:1235–1243.
- 19. Executive Committee for the Asymptomatic Carotid Atherosclerosis Study. Endarterectomy for asymptomatic carotid artery stenosis. *JAMA*. 1995;273: 1421–1428.
- 20. Brott T, Toole JF. Medical compared with surgical treatment of asymptomatic carotid artery stenosis. *Ann Intern Med.* 1995;123:720–722.
- 21. Stroke Unit Trialists' Collaboration. Collaborative systematic review of the randomised trials of organised inpatient (stroke unit) care after stroke. *BMJ.* 1997;314:1151–1159.
- 22. Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care after stroke. Cochrane Review. The Cochrane Library. Oxford: Update Software. 1998.
- 23. Kalra L. The influence of stroke unit rehabilitation on functional recovery from stroke. *Stroke*. 1994;25:821–825.
- 24. Indredavik B, Slordahl SA, Bakke F, Rokseth R, Haheim LL. Stroke unit treatment: Long-term effects. *Stroke*. 1997;28:1861–1866.
- 25. Indredavik B, Bakke F, Slordahl SA, Rokseth R, Haheim LL. Stroke unit treatment improves long-term quality of life: A randomized controlled trial. *Stroke*. 1998;29:895–899.
- 26. Ronning OM, Guldvog B. Stroke units versus general medical wards, I: Twelve- and eighteen-month survival: A randomized, controlled trial. *Stroke*. 1998:29:58–62.